BioNexus Gene Lab (NASDAQ:BGLC) versus Alignment Healthcare (NASDAQ:ALHC) Head-To-Head Comparison

BioNexus Gene Lab (NASDAQ:BGLCGet Free Report) and Alignment Healthcare (NASDAQ:ALHCGet Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Profitability

This table compares BioNexus Gene Lab and Alignment Healthcare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioNexus Gene Lab -24.26% -30.18% -24.85%
Alignment Healthcare -0.57% -16.23% -2.20%

Analyst Ratings

This is a summary of recent recommendations and price targets for BioNexus Gene Lab and Alignment Healthcare, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNexus Gene Lab 1 0 0 0 1.00
Alignment Healthcare 1 3 8 1 2.69

Alignment Healthcare has a consensus price target of $20.05, indicating a potential upside of 3.35%. Given Alignment Healthcare’s stronger consensus rating and higher possible upside, analysts plainly believe Alignment Healthcare is more favorable than BioNexus Gene Lab.

Institutional & Insider Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 86.2% of Alignment Healthcare shares are held by institutional investors. 0.7% of BioNexus Gene Lab shares are held by company insiders. Comparatively, 7.0% of Alignment Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

BioNexus Gene Lab has a beta of 5.24, suggesting that its stock price is 424% more volatile than the S&P 500. Comparatively, Alignment Healthcare has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.

Earnings and Valuation

This table compares BioNexus Gene Lab and Alignment Healthcare”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioNexus Gene Lab $9.51 million 0.82 -$1.60 million ($0.76) -5.70
Alignment Healthcare $2.70 billion 1.44 -$128.04 million ($0.12) -161.67

BioNexus Gene Lab has higher earnings, but lower revenue than Alignment Healthcare. Alignment Healthcare is trading at a lower price-to-earnings ratio than BioNexus Gene Lab, indicating that it is currently the more affordable of the two stocks.

Summary

Alignment Healthcare beats BioNexus Gene Lab on 12 of the 15 factors compared between the two stocks.

About BioNexus Gene Lab

(Get Free Report)

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About Alignment Healthcare

(Get Free Report)

Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.

Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.